# FES

Source: https://onco.cc/targets/fes/  
OnCo record `fes` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

FES (Tyrosine-protein kinase Fes/Fps) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer, Leukaemia and Colorectal cancer.

## Summary

Tyrosine-protein kinase that acts downstream of cell surface receptors and plays a role in the regulation of the actin cytoskeleton, microtubule assembly, cell attachment and cell spreading. Plays a role in FCER1 (high affinity immunoglobulin epsilon receptor)-mediated signalling in mast cells. Acts down-stream of the activated FCER1 receptor and the mast/stem cell growth factor receptor KIT.

Open Targets scores its association with cancer at 0.69 (direct and indirect evidence; datatypes literature 0.68, animal model 0.43, genetic association 0.47, somatic mutation 0.97). In OnCo, 1 product record names it (Fluoroestradiol F-18 (FES PET)).

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: FES proto-oncogene, tyrosine kinase; Tyrosine-protein kinase Fes/Fps
- Tags: cancer-genes-wave
- Symbol: FES
- Class: kinase
- Biology: Tyrosine-protein kinase that acts downstream of cell surface receptors and plays a role in the regulation of the actin cytoskeleton, microtubule assembly, cell attachment and cell spreading. Plays a role in FCER1 (high affinity immunoglobulin epsilon receptor)-mediated signalling in mast cells. Acts down-stream of the activated FCER1 receptor and the mast/stem cell growth factor receptor KIT. Plays a role in the regulation of mast cell degranulation. Plays a role in the regulation of cell differentiation and promotes neurite outgrowth in response to NGF signalling. Plays a role in cell scattering and cell migration in response to HGF-induced activation of EZR. Location: Cytoplasm, cytosol; Cytoplasm, cytoskeleton; Cell membrane; Cytoplasmic vesicle (UniProt). Locus 15q26.1 (HGNC).
- Where found: Skin cancer: Open Targets association 0.53 with skin cancer (MONDO_0002898); Leukaemia: Open Targets association 0.52 with leukaemia (MONDO_0005059); Colorectal cancer: Open Targets association 0.50 with colorectal cancer (MONDO_0005575)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: none stated by the sources. Evidence tier "association-only" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:3657: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3657
- UniProt P07332: https://www.uniprot.org/uniprotkb/P07332/entry
- NCBI Gene 2242: https://www.ncbi.nlm.nih.gov/gene/2242
- Ensembl ENSG00000182511: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000182511

## Connected records

- collections: [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)
- drugs: [Fluoroestradiol F-18 (FES PET)](https://onco.cc/drugs/fluoroestradiol-f18/)
- trials: [[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma](https://onco.cc/trials/nct04252859/), [18F-fluoroestradiol (FES) PET/CT for Breast Cancer](https://onco.cc/trials/nct04883814/), [Diagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breast Cancer](https://onco.cc/trials/nct01986569/), [FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy](https://onco.cc/trials/nct02398773/), [Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy](https://onco.cc/trials/nct04692103/), [Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer](https://onco.cc/trials/nct06260033/)

---
JSON: https://onco.cc/api/v1/entities/fes.json